Upsher-Smith Laboratories, LLC announced the recent launch of Famotidine for Oral Suspension, USP. The Famotidine Oral Suspension market had U.S. sales of approximately $73 million for the 12 months ending June 2023 according to IQVIA. The Therapeutic Equivalence (TE) code for Upsher-Smith's product is AB, and the original Reference Listed Drug (RLD) was the brand Pepcid® (famotidine) for oral suspension.
This product launch is a result of Upsher-Smith's strategic partnership with Appco Pharma LLC (Appco), a New Jersey-based generic drug development and manufacturing company.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!